Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administration of a 7-Valent Pneumococcal Conjugate Vaccine (Prevenar) and DTPa-HBV-IPV+Hib Vaccine (Infanrix Hexa) in Children at 2, 3, 4 and 11-14 Months of Age

Next Previous
Trial Profile

A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administration of a 7-Valent Pneumococcal Conjugate Vaccine (Prevenar) and DTPa-HBV-IPV+Hib Vaccine (Infanrix Hexa) in Children at 2, 3, 4 and 11-14 Months of Age

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Antipyretics
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Otitis media; Pertussis; Pneumococcal infections; Pneumonia; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth

    • Most Recent Events

    • 28 Feb 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top